Emerging treatments in Parkinson's disease

Research output: Contribution to journalArticle

Abstract

This paper provides a critical review on the most recent developments in the treatment of Parkinson's disease. New symptomatic therapies include the use of catechol-O-methyltransferase (COMT) inhibitors, new dopamine agonists and of surgical treatments (such as pallidotomy or deep brain stimulation). Protective strategies include the use of COMT and monoamine oxidase B inhibitors, of dopamine agonists and of trophic factors. The main preclinical premises, on which the usage of newly developed therapies is based, are discussed. Symptomatic therapy has been greatly refined in recent years and has gradually become a polytherapeutic approach. Protective therapy, which will attract the interest of fundamental and clinical research in the field of Parkinson's disease, is the real future challenge.

Original languageEnglish
Pages (from-to)175-183
Number of pages9
JournalEuropean Neurology
Volume38
Issue number3
Publication statusPublished - Oct 1997

Fingerprint

Parkinson Disease
Dopamine Agonists
Therapeutics
Pallidotomy
Catechol O-Methyltransferase
Deep Brain Stimulation
Monoamine Oxidase Inhibitors
Monoamine Oxidase
Research

Keywords

  • Dopamine
  • Dopamine agonists
  • Glutamate
  • Levodopa
  • Parkinson's disease
  • Receptors
  • Therapy

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Emerging treatments in Parkinson's disease. / Albanese, Alberto.

In: European Neurology, Vol. 38, No. 3, 10.1997, p. 175-183.

Research output: Contribution to journalArticle

@article{07583967b27f4120bc1a926894ad0a89,
title = "Emerging treatments in Parkinson's disease",
abstract = "This paper provides a critical review on the most recent developments in the treatment of Parkinson's disease. New symptomatic therapies include the use of catechol-O-methyltransferase (COMT) inhibitors, new dopamine agonists and of surgical treatments (such as pallidotomy or deep brain stimulation). Protective strategies include the use of COMT and monoamine oxidase B inhibitors, of dopamine agonists and of trophic factors. The main preclinical premises, on which the usage of newly developed therapies is based, are discussed. Symptomatic therapy has been greatly refined in recent years and has gradually become a polytherapeutic approach. Protective therapy, which will attract the interest of fundamental and clinical research in the field of Parkinson's disease, is the real future challenge.",
keywords = "Dopamine, Dopamine agonists, Glutamate, Levodopa, Parkinson's disease, Receptors, Therapy",
author = "Alberto Albanese",
year = "1997",
month = "10",
language = "English",
volume = "38",
pages = "175--183",
journal = "European Neurology",
issn = "0014-3022",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Emerging treatments in Parkinson's disease

AU - Albanese, Alberto

PY - 1997/10

Y1 - 1997/10

N2 - This paper provides a critical review on the most recent developments in the treatment of Parkinson's disease. New symptomatic therapies include the use of catechol-O-methyltransferase (COMT) inhibitors, new dopamine agonists and of surgical treatments (such as pallidotomy or deep brain stimulation). Protective strategies include the use of COMT and monoamine oxidase B inhibitors, of dopamine agonists and of trophic factors. The main preclinical premises, on which the usage of newly developed therapies is based, are discussed. Symptomatic therapy has been greatly refined in recent years and has gradually become a polytherapeutic approach. Protective therapy, which will attract the interest of fundamental and clinical research in the field of Parkinson's disease, is the real future challenge.

AB - This paper provides a critical review on the most recent developments in the treatment of Parkinson's disease. New symptomatic therapies include the use of catechol-O-methyltransferase (COMT) inhibitors, new dopamine agonists and of surgical treatments (such as pallidotomy or deep brain stimulation). Protective strategies include the use of COMT and monoamine oxidase B inhibitors, of dopamine agonists and of trophic factors. The main preclinical premises, on which the usage of newly developed therapies is based, are discussed. Symptomatic therapy has been greatly refined in recent years and has gradually become a polytherapeutic approach. Protective therapy, which will attract the interest of fundamental and clinical research in the field of Parkinson's disease, is the real future challenge.

KW - Dopamine

KW - Dopamine agonists

KW - Glutamate

KW - Levodopa

KW - Parkinson's disease

KW - Receptors

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0030883661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030883661&partnerID=8YFLogxK

M3 - Article

C2 - 9363829

AN - SCOPUS:0030883661

VL - 38

SP - 175

EP - 183

JO - European Neurology

JF - European Neurology

SN - 0014-3022

IS - 3

ER -